Hairy cell leukemia · 7 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bendamustine and Rituximab (BR) Variant #12 | — | R 40 807 | 28d | ~39.6 mo | — | ~44 | ~R 1 795 506 PFS proxy · indirect | 18 |
Cladribine and Rituximab Variant #01 | — | R 33 968 | 21d | — | — | — | — | — |
Vemurafenib monotherapy Variant #01 | — | R 13 464 | 28d | ~7.2 mo | ~15.5 mo | ~8 | ~R 107 711 PFS proxy · indirect | 4 |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~20.3 mo | — | ~4 | ~R 208 PFS proxy · indirect | 17 |
Moxetumomab pasudotox monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
Interferon alfa-2a monotherapy Variant #01 Partial | — | — | 7d | ~5.4 mo | ~17.5 mo | ~24 | — | 10 |
Interferon alfa-2b monotherapy Variant #01 Partial | — | — | 28d | ~13.2 mo | — | ~15 | — | 2 |
7 of 7 regimens shown